Operating leases and R&D question

I ran into this http://pages.stern.nyu.edu/~adamodar/New_Home_Pag… while building a DCF model. Damoradan says, in his response to question #1, that the EBIT listed on the income statement must be adjusted as operating leases and R&D are not operating expenses. Searching WSO, I came across this thread //www.wallstreetoasis.com/forums/operating-leases which has a post by cdnbanker that goes:

"The OP is referring a technique of standardizing EBITDA some valuation methods call for in order to create more comparability between companies that borrow money to buy their PP&E and companies that rent their PP&E. In that case, capitalized operating leases are just treated like debt, and thus included in EV.

But as hardbanker mentioned, this is a theoretical approach rarely seen in practice in IB. In most cases, we just use the quick-and-dirty method of looking at EBITDAR (R = rent). Hope this helps."

Does this mean that in practice in IB one would adjust net income listed on the income statement by adding back R&D and operating lease costs to arrive at EBIT used in FCF (and if R&D is a capex, wouldn't it be cancelled out if one added it to to both net income and capex in EBIT(1-t) + D&A - capex - delta working capital? If not, someone please enlighten me about their quick-and-dirty method, because that's how I like it.

5 Comments
 
Best Response

I guess this question would be easier to answer if I could show you a model and how it works, but hopefully you can follow. The R&D wouldn't be cancelled out because you're going to remove it from teh income statement and make it capex. The idea is to treat R&D just like you treat PP&E. So it goes into capex and gets amortized over the valuable life of the research. Does PP&E get cancelled out? No, the amortization of teh R&D gets cancelled out but it still shows up in the capex as far as your free cash flows.

As far as operating leases, the quickest way, imo, is to just treat capitalized leases like debt, that way it makes it more apples to apples. Often, you have to go digging through 10-K to find operating leases whereas capital leases will show up on the balance sheet. Try it a few times with a few different companies; I think you'll find that adding cap leases as if they're debt is much easier than trying to find an EBITDAR (and EBITDAR is more for industries with a heavy real estate component, since usually the rent they're referring to is more akin to renting property, not equipment).

 

So I add R&D back to operating profit, then amortize it over what I think the valuable life of the research is (any tips on how I should choose such a length? Let's say I choose 5 yrs - if R&D is 100, then I have amortization of 20/yr, correct?). Then, I add R&D to capex and the amortization of R&D to my depreciation/amortization value?

Aren't operating leases different than capital leases?

Also, I'm a little confused about how to interpret the 10-K reporting of operating leases. Operating leases are listed by Payment Due By Period and there is total, 1 yr, 1-3 yrs, 5 yrs, etc., but only has operating lease values for 1 yr, and 1-3 yrs. 5 yrs + are left blank. Do I interpret this as the 1 yr. section being the operating lease expense for that year?

Some context: the company I'm valuing currently has no debt and has never had debt. If I treat operating leases as debt, then I can't just ignore the debt weighted portion of WACC, correct? Operating lease would then be my market value of debt... but what about cost of debt? The company I'm valuing technically has a AAA rating because it has an infinite interest coverage ratio. Do I use cost of debt that reflects AAA, or do I downgrade to AA (comparable company has AA rating w/ debt)?

A lot of questions.

Thanks for your help.

 

Voluptatum quam quia quia exercitationem et. Quidem vel et omnis delectus similique omnis. Neque veniam quia sit. Voluptas maiores fugit saepe praesentium.

Molestiae totam porro earum dolores officiis aperiam. Qui dolores nobis dignissimos et placeat. Aut fugiat quis est ut. Ipsam vel sit quidem ab vero ut. Voluptatem adipisci fugit aut occaecati. Occaecati molestiae non magni. Dolorem eaque harum sunt vel quia ullam quia consequatur.

Rerum esse sunt quaerat dolorum rerum excepturi. Quo et deserunt provident tenetur nulla dolores molestias. Quia eos sapiente iure exercitationem. Facilis autem non molestias eos voluptatum et vel.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 01 98.3%
  • BMO Capital Markets 13 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (15) $434
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (80) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
dosk17's picture
dosk17
98.9
6
DrApeman's picture
DrApeman
98.9
7
Betsy Massar's picture
Betsy Massar
98.9
8
GameTheory's picture
GameTheory
98.9
9
CompBanker's picture
CompBanker
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”